2072 - Clinical Evaluation of the BioFire® Global Fever Special Pathogens Panel

Presenting Author(s)

• 

  Brittany Collins, PhD (she/her/hers)

  Clinical Research Scientist
  BioFire Defense, LLC
  Salt Lake City, UT, United States

  Slides

Co-Author(s)

• DR

  David S. Rabiger, PhD

  Scientist
  BioFire Defense
  Salt Lake City, Utah, United States
• MG

  Mark Gurling, PhD

  Scientist for Regulated Products
  BioFire Defense, LLC
  Salt Lake City UT USA, Utah, United States
• JH

  Jared R. Helm, PhD

  Scientist
  BioFire Defense LLC
  Riverton, Utah, United States
• WS

  Wendy Smith, PhD

  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• PB

  Pascal Belgique, BS

  Research Associate I
  BioFire Defense
  Murray, Utah, United States
• OJ

  Olivia Jackson, n/a

  Data Specialist
  BioFire Defense
  Sandy, Utah, United States
• MJ

  Michael Johnson, n/a

  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• AK

  Alex J. Kelley, n/a

  Research Associate
  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• HV

  Hannah VanHollebeke, n/a

  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• SW

  Sidney Webster, n/a

  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• AW

  Ashley Wiltsie, B.S. in Biology

  Research Associate I
  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• MK

  Marianne Kim, PhD

  BioFire Defense, LLC
  Salt Lake City, Utah, United States
• CP

  Cynthia L. Phillips, PhD

  VP Regulatory, Quality & Clinical Affairs
  BioFire Defense
  Salt Lake City, Utah, United States